CONMED Co. (NASDAQ:CNMD) declared a quarterly dividend on Friday, November 9th, Wall Street Journal reports. Stockholders of record on Friday, December 14th will be given a dividend of 0.20 per share by the medical technology company on Monday, January 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Thursday, December 13th.

CONMED has a payout ratio of 36.9% meaning its dividend is sufficiently covered by earnings. Equities analysts expect CONMED to earn $2.42 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 33.1%.

CNMD stock opened at $69.10 on Friday. CONMED has a twelve month low of $49.22 and a twelve month high of $83.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.15 and a current ratio of 2.20. The stock has a market cap of $1.93 billion, a PE ratio of 36.56, a P/E/G ratio of 2.75 and a beta of 0.68.

CONMED (NASDAQ:CNMD) last posted its quarterly earnings data on Thursday, November 1st. The medical technology company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.01. CONMED had a return on equity of 9.51% and a net margin of 8.56%. The firm had revenue of $202.30 million for the quarter, compared to analysts’ expectations of $198.51 million. During the same period in the previous year, the firm earned $0.42 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, equities analysts forecast that CONMED will post 2.17 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on CNMD shares. Zacks Investment Research raised CONMED from a “sell” rating to a “hold” rating in a research report on Tuesday, September 25th. Needham & Company LLC lifted their price objective on CONMED from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. BidaskClub cut CONMED from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 17th. Barclays set a $78.00 price target on CONMED and gave the stock an “equal weight” rating in a report on Tuesday, October 16th. Finally, Leerink Swann boosted their price target on CONMED from $76.00 to $81.00 and gave the stock a “market perform” rating in a report on Thursday, August 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. CONMED has an average rating of “Hold” and an average price target of $81.50.

In related news, VP Stanley W. Peters III sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $80.43, for a total value of $120,645.00. Following the transaction, the vice president now directly owns 1,496 shares of the company’s stock, valued at approximately $120,323.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Heather L. Cohen purchased 900 shares of the stock in a transaction that occurred on Tuesday, November 6th. The stock was acquired at an average cost of $68.60 per share, for a total transaction of $61,740.00. The disclosure for this purchase can be found here. 3.13% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.

Further Reading: Discover Your Risk Tolerance

Dividend History for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with's FREE daily email newsletter.